Industry snapshot
Key public data points
Historical & forecast
Base year 2025. Each series is official through its own latest government-data year (shown in the legend on each chart), and years beyond that are Claight estimates. As of July 2026 the current year is still in progress (2026 annual data is not yet published), so the forecast runs to 2030.
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Industry Definition and Scope
What does the Contraceptive Tablet Manufacturing in the US industry cover?
The contraceptive tablet manufacturing industry encompasses companies that produce oral contraceptive pills, including combination estrogen-progestin and progestin-only formulations. This includes both branded and generic versions of birth control pills, which are prescription medications designed to prevent pregnancy through hormonal regulation.
- •The industry primarily manufactures oral contraceptives in tablet form, including combination pills (containing both estrogen and progestin) and progestin-only pills ('mini-pills')
- •Manufacturing facilities must comply with Current Good Manufacturing Practices (cGMP) established by the FDA
- •Products are distributed through pharmacies, healthcare providers, and mail-order prescription services
Market Structure and Operators
Who operates in the industry and how is it structured?
The contraceptive tablet market operates as a moderately concentrated industry with several major pharmaceutical manufacturers dominating the branded segment while numerous companies compete in the generic space. Market share is influenced by patent expirations, regulatory approvals, and distribution networks.
- •The branded contraceptive market is dominated by companies like Teva Pharmaceuticals, Actavis (owned by Allergan), and Pfizer
- •Generic manufacturers including Mylan (now part of Upjohn), Amneal Pharmaceuticals, and Lannett Company produce off-patent contraceptive formulations
- •Market concentration varies between branded (more concentrated) and generic (more fragmented) segments
- •Production facilities are strategically located near major pharmaceutical hubs including New Jersey, Pennsylvania, and California
Demand Drivers
What drives demand in the industry?
Demand for contraceptive tablets is primarily driven by population demographics, healthcare access, and evolving consumer preferences for birth control options. The market is influenced by prescription patterns, insurance coverage, and awareness of contraceptive methods.
- •Approximately 64% of women aged 15-49 in the US use contraception, with oral contraceptives being the most common method after sterilization (CDC National Survey of Family Growth, 2017-2019)
- •The Affordable Care Act (ACA) requires most insurance plans to cover FDA-approved contraceptives without cost-sharing, improving access
- •Changing consumer preferences toward longer-acting reversible contraceptives (LARCs) like IUDs have reduced market share growth for oral contraceptives
- •Population growth and increasing awareness of family planning options support steady demand in the contraceptive market
Competitive Landscape and Notable Public Companies
Who are the notable companies in the industry?
The contraceptive tablet market features both multinational pharmaceutical giants and specialized generic manufacturers. Competition is based on pricing, formulation innovations, patent strategies, and regulatory approvals for new combination therapies.
- •Pfizer produces branded oral contraceptives including Lo Loestrin Fe and Yaz/Yasmin
- •Teva Pharmaceuticals manufactures generic and branded contraceptive formulations including Sprintec and Seasonique
- •Novartis through its subsidiary Sandoz produces generic oral contraceptives
- •Allergan (now AbbVie) produces branded contraceptives including Loestrin and Loestrin Fe
Recent Trends and Outlook
What are the recent trends and outlook?
The contraceptive tablet manufacturing industry has seen significant shifts due to patent cliffs, regulatory changes, and emerging alternatives. The market faces pressure from generic competition while adapting to consumer preferences for non-oral contraceptives and innovative formulations.
- •The market for oral contraceptives has experienced declining growth rates compared to previous decades, with CAGR estimated at 1-2% over the past five years (IQVIA, 2023)
- •Increased focus on combination contraceptives with additional benefits such as acne treatment and PMDD relief
- •Growing interest in extended-cycle and continuous-use formulations reduces monthly dosing frequency
- •Manufacturers are developing combination products with novel progestins to minimize side effects and improve efficacy
Regulation and Compliance
How is the industry regulated?
Contraceptive tablet manufacturers operate under strict regulatory oversight from the FDA, which requires extensive clinical trials and safety testing before market approval. Post-approval monitoring and quality controls are essential to maintain compliance and market access.
- •All oral contraceptives require New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) approval from the FDA
- •Manufacturing facilities must comply with 21 CFR Part 210 and 211 (cGMP) regulations
- •Post-market adverse event reporting to the FDA's Adverse Event Reporting System (AERS) is mandatory
- •The Risk Evaluation and Mitigation Strategy (REMS) program may be required for certain high-risk contraceptive formulations
Sources
Government, statistical and trade sources used for this Claight analysis.
- IQVIA Institute for Human Data Science (2023) ·
- CDC National Center for Health Statistics (2019) ·
- U.S. Food and Drug Administration (2023) ·
- Centers for Medicare & Medicaid Services (2023)
Claight analysis of public industry data.